Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for severe COVID-19 pneumonia failing glucocorticoids
2020-005291-35Phase 3Terminated
- Sponsor
- AOU Policlinico di Modena
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in Coronavirus disease 2019 pneumonia comparing Tocilizumab plus standard of care with Standard of care (2 arms). Primary endpoint: Intubation or death or equivalent severe outcome within 4 weeks. Started Mar 2021; status: terminated.
02
Drugs
tocilizumab
03
Conditions
Coronavirus disease 2019 pneumonia
Beyond the preview
Go deeper on 2020-005291-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005291-35.